Aspira Women’s Health (NASDAQ:AWH – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday.
Aspira Women’s Health Trading Up 1.1 %
Shares of Aspira Women’s Health stock traded up $0.04 on Friday, reaching $3.65. The stock had a trading volume of 14,010 shares, compared to its average volume of 32,870. Aspira Women’s Health has a 1 year low of $2.31 and a 1 year high of $7.50. The company has a market cap of $37.74 million, a P/E ratio of -0.30 and a beta of 1.66. The business’s 50 day moving average is $4.37 and its two-hundred day moving average is $4.34.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Northeast Financial Consultants Inc bought a new position in shares of Aspira Women’s Health in the third quarter worth approximately $126,000. Northern Trust Corp boosted its holdings in Aspira Women’s Health by 227.7% in the fourth quarter. Northern Trust Corp now owns 36,049 shares of the company’s stock valued at $147,000 after acquiring an additional 25,047 shares in the last quarter. Atria Wealth Solutions Inc. bought a new stake in Aspira Women’s Health in the first quarter valued at $49,000. Perkins Capital Management Inc. bought a new stake in Aspira Women’s Health in the third quarter valued at $268,000. Finally, Quantum Private Wealth LLC boosted its holdings in Aspira Women’s Health by 76.8% in the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after acquiring an additional 21,788 shares in the last quarter. Institutional investors own 31.85% of the company’s stock.
About Aspira Women’s Health
Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.
Further Reading
- Five stocks we like better than Aspira Women’s Health
- How to Calculate Return on Investment (ROI)
- KB Home: Building on Strong Foundations During Volatile Times
- Stock Splits, Do They Really Impact Investors?
- Nike Stock and the 30% Rally That’s Expected
- What is Short Interest? How to Use It
- Headwinds for Darden Restaurants are an Opportunity For Investors
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.
